eRBCDet: Blood Cell RNA-Based Cancer Detection

Sponsor
Wuhan Union Hospital, China (Other)
Overall Status
Recruiting
CT.gov ID
NCT05839834
Collaborator
(none)
5,000
1
44
113.7

Study Details

Study Description

Brief Summary

Early diagnosis of cancer may provide patients with more treatment options and hopefully prolong survival. The purpose of this multi-center study is to collect peripheral blood from newly diagnosed cancer patients and healthy donors to establish a blood cell RNA-based model for the differentiation of cancer patients and healthy donors. The area under the receiver operating characteristic (AUROC), sensitivity and specificity of the test in the early detection of multiple cancers will be measured.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Blood test

Study Design

Study Type:
Observational
Anticipated Enrollment :
5000 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
A Blinded Prospective Study on Development and Validation of the Blood Cell RNA-Based Cancer Detection
Actual Study Start Date :
Feb 8, 2021
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Oct 8, 2024

Arms and Interventions

Arm Intervention/Treatment
Cancer

Patients with new diagnosis of cancers

Diagnostic Test: Blood test
RNA sequencing of peripheral blood cells

Non-cancer

Healthy participants

Diagnostic Test: Blood test
RNA sequencing of peripheral blood cells

Outcome Measures

Primary Outcome Measures

  1. Sensitivity and specificity of cancer detection [1 year]

    Sensitivity and specificity of the early detection of 30 types of cancers of a blood cell RNA-based cancer detection test

  2. Accuracy of TOO prediction [1 year]

    Accuracy of the tissue of origin (TOO) prediction of a blood cell RNA-based cancer detection test

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes

Inclusion Criteria for All the Participants

  1. Age 18 years or older

  2. Provide informed consent

Exclusion Criteria for All the Participants:
  1. Pregnancy or lactating women

  2. Received a blood transfusion within 1 month

  3. Received anti-cancer treatment within 3 years

  4. Known prior diagnosis of cancer

  5. Poor health status or unfit to tolerate blood draw

Contacts and Locations

Locations

Site City State Country Postal Code
1 Zheng Wang Wuhan Hubei China 430022

Sponsors and Collaborators

  • Wuhan Union Hospital, China

Investigators

  • Study Chair: Zheng Wang, MD/PhD, Wuhan Union Hospital, China

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Zheng Wang, MD/PhD, Study chair, Clinical Professor, Wuhan Union Hospital, China
ClinicalTrials.gov Identifier:
NCT05839834
Other Study ID Numbers:
  • blood-cell-RNA
First Posted:
May 3, 2023
Last Update Posted:
May 3, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of May 3, 2023